Genomic sequence, organization, and chromosomal localization of human JAK3 - PubMed (original) (raw)
Genomic sequence, organization, and chromosomal localization of human JAK3
M C Riedy et al. Genomics. 1996.
Abstract
Members of the Janus (JAK) protein tyrosine kinase family including JAK3 have recently emerged as important components in cytokine signal transduction. Mutations of JAK3 have been found in a number of patients who present with severe combined immunodeficiency. To facilitate the further identification of JAK3-SCID patients and to understand the structure of JAK3 better, we undertook the determination of the genomic sequence, organization, and chromosomal localization of the JAK3 gene. The JAK3 gene was found to consist of 19 exons and 18 introns. Interestingly, the organization of the kinase-(JH1) and pseudokinase-(JH2) domains were found to be dissimilar. In addition, the JAK3 gene was localized to human chromosome 19p13.1. These data should facilitate the identification of patients with this new form of immunodeficiency and will provide insight into the structure of this kinase.
Similar articles
- Structural organization and chromosomal mapping of JAK3 locus.
Kumar A, Toscani A, Rane S, Reddy EP. Kumar A, et al. Oncogene. 1996 Nov 7;13(9):2009-14. Oncogene. 1996. PMID: 8934548 - Genomic structure and promoter region of the murine Janus-family tyrosine kinase, Jak3.
Gurniak CB, Thomis DC, Berg LJ. Gurniak CB, et al. DNA Cell Biol. 1997 Jan;16(1):85-94. doi: 10.1089/dna.1997.16.85. DNA Cell Biol. 1997. PMID: 9022047 - Revised exon-intron structure of human JAK3 locus.
Brooimans RA, van der Slot AJ, van den Berg AJ, Zegers BJ. Brooimans RA, et al. Eur J Hum Genet. 1999 Oct-Nov;7(7):837-40. doi: 10.1038/sj.ejhg.5200375. Eur J Hum Genet. 1999. PMID: 10573019 - Jak3 and the pathogenesis of severe combined immunodeficiency.
O'Shea JJ, Husa M, Li D, Hofmann SR, Watford W, Roberts JL, Buckley RH, Changelian P, Candotti F. O'Shea JJ, et al. Mol Immunol. 2004 Jul;41(6-7):727-37. doi: 10.1016/j.molimm.2004.04.014. Mol Immunol. 2004. PMID: 15220007 Review. - Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.
Notarangelo LD, Mella P, Jones A, de Saint Basile G, Savoldi G, Cranston T, Vihinen M, Schumacher RF. Notarangelo LD, et al. Hum Mutat. 2001 Oct;18(4):255-63. doi: 10.1002/humu.1188. Hum Mutat. 2001. PMID: 11668610 Review.
Cited by
- Inhibiting interferon pathways in dermatomyositis: rationale and preliminary evidence.
Casal-Dominguez M, Pinal-Fernandez I, Mammen AL. Casal-Dominguez M, et al. Curr Treatm Opt Rheumatol. 2021 Sep;7(3):258-271. doi: 10.1007/s40674-021-00182-1. Epub 2021 Jun 14. Curr Treatm Opt Rheumatol. 2021. PMID: 37456764 Free PMC article. - Case Report: Mutations in JAK3 causing severe combined immunodeficiency complicated by disseminated Bacille Calmette-Guérin disease and Pneumocystis pneumonia.
Pan Y, Pan H, Lian C, Wu B, Lin J, Huang G, Cui B. Pan Y, et al. Front Immunol. 2022 Nov 17;13:1055607. doi: 10.3389/fimmu.2022.1055607. eCollection 2022. Front Immunol. 2022. PMID: 36466884 Free PMC article. - JAK Kinases in Health and Disease: An Update.
Laurence A, Pesu M, Silvennoinen O, O'Shea J. Laurence A, et al. Open Rheumatol J. 2012;6:232-44. doi: 10.2174/1874312901206010232. Epub 2012 Sep 7. Open Rheumatol J. 2012. PMID: 23028408 Free PMC article. - Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.
Mascarenhas J, Mughal TI, Verstovsek S. Mascarenhas J, et al. Curr Med Chem. 2012;19(26):4399-413. doi: 10.2174/092986712803251511. Curr Med Chem. 2012. PMID: 22830345 Free PMC article. Review. - Janus kinase 3: the controller and the controlled.
Wu W, Sun XH. Wu W, et al. Acta Biochim Biophys Sin (Shanghai). 2012 Mar;44(3):187-96. doi: 10.1093/abbs/gmr105. Epub 2011 Nov 29. Acta Biochim Biophys Sin (Shanghai). 2012. PMID: 22130498 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases